{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:51:28Z","timestamp":1791355888495,"version":"4.3.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s11899-017-0366-1","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T02:05:29Z","timestamp":1487037929000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"12","author":[{"given":"Mazie","family":"Tsang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"366_CR1","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.leukres.2009.07.005","volume":"33","author":"T Hamblin","year":"2009","unstructured":"Hamblin T. Just how exactly common is CLL? Leuk Res. 2009;33:1452\u20133.","journal-title":"Leuk Res"},{"key":"366_CR2","unstructured":"SEER Cancer Statistics Review, 1975\u20132012, National Cancer Institute. (Accessed October, 2015, at http:\/\/seer.cancer.gov\/csr\/1975_2012\/ .)"},{"key":"366_CR3","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","volume":"121","author":"S Parikh","year":"2015","unstructured":"Parikh S, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121:2883\u201391.","journal-title":"Cancer"},{"key":"366_CR4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4049\/jimmunol.122.3.1087","volume":"122","author":"N Chiorazzi","year":"1979","unstructured":"Chiorazzi N, Fu SM, Montazeri G, et al. T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol. 1979;122:1087\u201390.","journal-title":"J Immunol"},{"key":"366_CR5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood.V57.3.418.418","volume":"57","author":"N Kay","year":"1981","unstructured":"Kay N. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood. 1981;57:418\u201320.","journal-title":"Blood"},{"key":"366_CR6","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.4049\/jimmunol.129.5.2305","volume":"129","author":"C Platsoucas","year":"1982","unstructured":"Platsoucas C, Galinski M, Kempin S, et al. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. J Immunol. 1982;129:2301\u201312.","journal-title":"J Immunol"},{"key":"366_CR7","first-page":"1509","volume":"10","author":"M Schlesinger","year":"1996","unstructured":"Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia. 1996;10:1509\u201313.","journal-title":"Leukemia"},{"key":"366_CR8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3109\/10428194.2012.750723","volume":"54","author":"D Kontoyiannis","year":"2013","unstructured":"Kontoyiannis D, Georgiadou SP, Wierda WG, et al. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1730\u20133.","journal-title":"Leuk Lymphoma"},{"key":"366_CR9","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","volume":"116","author":"C Moreno","year":"2010","unstructured":"Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116:4771\u20136.","journal-title":"Blood"},{"key":"366_CR10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2008.07086.x","volume":"141","author":"C Zent","year":"2008","unstructured":"Zent C, Wei D, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukemia\/small lymphocytic leukemia (CLL). Br J Haematol. 2008;141:615\u201321.","journal-title":"Br J Haematol"},{"key":"366_CR11","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"B Cheson","year":"1996","unstructured":"Cheson B, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990\u20137.","journal-title":"Blood"},{"key":"366_CR12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/CCO.0b013e328348c683","volume":"23","author":"P Strati","year":"2011","unstructured":"Strati P, Caligaris-Cappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? Curr Opin Oncol. 2011;23:455\u201360.","journal-title":"Curr Opin Oncol"},{"key":"366_CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2010.01.004","volume":"23","author":"C Zent","year":"2010","unstructured":"Zent C, Kay NE. Autoimmune complications in chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol. 2010;23:47\u201359.","journal-title":"Best Pract Res Clin Haematol"},{"key":"366_CR14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428190903026492","volume":"50","author":"C Zent","year":"2009","unstructured":"Zent C, Wei D, Reinalda MS, et al. Autoimmune cytopenia in chronic lymphocytic leukemia\/small lymphocytic leukemia (CLL): changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50:1261\u20138.","journal-title":"Leuk Lymphoma"},{"key":"366_CR15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3324\/haematol.2010.036152","volume":"96","author":"KFG Hodgson","year":"2011","unstructured":"Hodgson KFG, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96:752\u201361.","journal-title":"Haematologica"},{"key":"366_CR16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","volume":"89","author":"C Visco","year":"2014","unstructured":"Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014;89:1055\u201362.","journal-title":"Am J Hematol"},{"key":"366_CR17","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2003-10-3563","volume":"105","author":"A Hall","year":"2005","unstructured":"Hall A, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105:2007\u201315.","journal-title":"Blood"},{"key":"366_CR18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jcp.39.7.713","volume":"39","author":"T Hamblin","year":"1986","unstructured":"Hamblin T, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986;39:713\u20136.","journal-title":"J Clin Pathol"},{"key":"366_CR19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2010.09.006","volume":"20","author":"J Riches","year":"2010","unstructured":"Riches J, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukemia. Semin Cancer Biol. 2010;20:431\u20138.","journal-title":"Semin Cancer Biol"},{"key":"366_CR20","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3109\/10428194.2014.986479","volume":"56","author":"D Lad","year":"2015","unstructured":"Lad D, Varma S, Varma N, et al. Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma. 2015;56:2424\u20138.","journal-title":"Leuk Lymphoma"},{"key":"366_CR21","doi-asserted-by":"crossref","unstructured":"Spitzer M, Gherardini, PF, Fragiadakis, GK, et al. An interactive reference framework for modeling a dynamic immune system. Science 2015.;349.","DOI":"10.1126\/science.1259425"},{"key":"366_CR22","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2015-10-620864","volume":"127","author":"S Parikh","year":"2016","unstructured":"Parikh S, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127:1752\u201360.","journal-title":"Blood"},{"key":"366_CR23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3109\/10428194.2013.856426","volume":"55","author":"W Barcellini","year":"2014","unstructured":"Barcellini W, Imperiali FG, Zaninoni A, et al. Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression. Leuk Lymphoma. 2014;55:1768\u201373.","journal-title":"Leuk Lymphoma"},{"key":"366_CR24","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1998.16.5.1885","volume":"16","author":"R Weiss","year":"1998","unstructured":"Weiss R, Freiman J, Kweder SL, et al. Haemolytic anaemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998;16:1885\u20139.","journal-title":"J Clin Oncol"},{"key":"366_CR25","first-page":"113","volume":"40","author":"H Gonazalez","year":"1998","unstructured":"Gonazalez H, Leblond V, Azar N, et al. Severe autoimmune haemolytic anaemia in eight patients treated with fludarabine. Hematol Cell Ther. 1998;40:113\u20138.","journal-title":"Hematol Cell Ther"},{"key":"366_CR26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.leukres.2016.09.002","volume":"50","author":"S Molica","year":"2016","unstructured":"Molica S, Polliack A. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leuk Res. 2016;50:31\u20136.","journal-title":"Leuk Res"},{"key":"366_CR27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208\u201315.","journal-title":"Blood"},{"key":"366_CR28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ajh.23268","volume":"87","author":"G Reda","year":"2012","unstructured":"Reda G, Maura F, Gritti G, et al. Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. Am J Hematol. 2012;87:936\u20137.","journal-title":"Am J Hematol"},{"key":"366_CR29","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/blood.V126.23.4169.4169","volume":"126","author":"M Tsang","year":"2015","unstructured":"Tsang M, Chaffee KR, Call TG, et al. Pure red cell aplasia (PRCA) in chronic lymphocytic leukemia (CLL): etiology, therapy, and outcomes. Blood. 2015;126:4169.","journal-title":"Blood"},{"key":"366_CR30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/10428191003682767","volume":"51","author":"CT Bowen DA","year":"2010","unstructured":"DA Bowen CT, Shanafelt TD, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia\/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010;51:620\u20137.","journal-title":"Leuk Lymphoma"},{"key":"366_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10369","volume":"74","author":"M Kyasa","year":"2003","unstructured":"Kyasa M, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Am J Hematol. 2003;74:1\u20138.","journal-title":"Am J Hematol"},{"key":"366_CR32","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.23861","volume":"90","author":"A Quinquenel","year":"2015","unstructured":"Quinquenel A, Al Nawakil C, Baran-Marszak F, et al. Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients. Am J Hematol. 2015;90:E5\u20138.","journal-title":"Am J Hematol"},{"key":"366_CR33","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1182\/blood.V95.9.2786.009k30_2786_2792","volume":"95","author":"F Mauro","year":"2000","unstructured":"Mauro F, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95:2786\u201392.","journal-title":"Blood"},{"key":"366_CR34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ajh.10210","volume":"71","author":"W Barcellini","year":"2002","unstructured":"Barcellini W, Montesano R, Clerici G, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol. 2002;71:177\u201383.","journal-title":"Am J Hematol"},{"key":"366_CR35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.seminoncol.2016.02.011","volume":"43","author":"K Rogers","year":"2016","unstructured":"Rogers K, Woyach JA. Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Semin Oncol. 2016;43:300\u201310.","journal-title":"Semin Oncol"},{"key":"366_CR36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.20671","volume":"81","author":"G Pamuk","year":"2006","unstructured":"Pamuk G, Turgut B, Demir M, et al. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. Am J Hematol. 2006;81:631\u20133.","journal-title":"Am J Hematol"},{"key":"366_CR37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","volume":"81","author":"G D\u2019Arena","year":"2006","unstructured":"D\u2019Arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81:598\u2013602.","journal-title":"Am J Hematol"},{"key":"366_CR38","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","volume":"119","author":"W Barcellini","year":"2012","unstructured":"Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119:3691\u20137.","journal-title":"Blood"},{"key":"366_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cei.12697","volume":"183","author":"A Church","year":"2016","unstructured":"Church A, VanDerMeid KR, Baig NA, et al. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages. Clin Exp Immunol. 2016;183:90\u2013101.","journal-title":"Clin Exp Immunol"},{"key":"366_CR40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.leu.2404512","volume":"21","author":"C Karlsson","year":"2007","unstructured":"Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21:511\u20134.","journal-title":"Leukemia"},{"key":"366_CR41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2007.06513.x","volume":"136","author":"G Borthakur","year":"2007","unstructured":"Borthakur G, O\u2019Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludrabine, cyclophosphamide and rituximab\u2014incidence and predictors. Br J Haematol. 2007;136:800\u20135.","journal-title":"Br J Haematol"},{"key":"366_CR42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.23909","volume":"90","author":"A Quinquenel","year":"2015","unstructured":"Quinquenel A, Willekens C, Dupuis J, et al. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC\/MW and GOELAMS). Am J Hematol. 2015;90:204\u20137.","journal-title":"Am J Hematol"},{"key":"366_CR43","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","volume":"16","author":"N Gupta","year":"2002","unstructured":"Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotheray for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092\u20135.","journal-title":"Leukemia"},{"key":"366_CR44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3109\/10428194.2011.591005","volume":"52","author":"A Michallet","year":"2011","unstructured":"Michallet A, Rossignol J, Cazin B, et al. Rituximab\u2013cyclophosphamide\u2013dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52:1401\u20133.","journal-title":"Leuk Lymphoma"},{"key":"366_CR45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00280-007-0651-0","volume":"62","author":"M Gentile","year":"2008","unstructured":"Gentile M, Lucia E, Iorio C, et al. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient. Cancer Chemother Pharmacol. 2008;62:741\u20133.","journal-title":"Cancer Chemother Pharmacol"},{"key":"366_CR46","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","volume":"100","author":"UPWW Hegde","year":"2002","unstructured":"Hegde UPWW, White T, et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260\u20132.","journal-title":"Blood"},{"key":"366_CR47","first-page":"ELT02","volume":"88","author":"M Fernandez","year":"2003","unstructured":"Fernandez M, Llopis I, Pastor E, et al. Immune thrombocytoepnia induced by fludarabine successfully treated with rituximab. Haematologica. 2003;88:ELT02.","journal-title":"Haematologica"},{"key":"366_CR48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/10428190902887563","volume":"50","author":"MLS Kaufman","year":"2009","unstructured":"Kaufman MLS, Driscoll N, et al. A combination of rituximab, cyclophosphamide, and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:892\u20139.","journal-title":"Leuk Lymphoma"},{"key":"366_CR49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","author":"J Bussel","year":"2009","unstructured":"Bussel J, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641\u20138.","journal-title":"Lancet"},{"key":"366_CR50","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","volume":"363","author":"D Kuter","year":"2010","unstructured":"Kuter D, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889\u201399.","journal-title":"N Engl J Med"},{"key":"366_CR51","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/imj.12468","volume":"44","author":"E Jolliffe","year":"2014","unstructured":"Jolliffe E, Romeril K. Eltrombopag for resistant immune thrombocytopenia secondary to secondary lymphocytic leukemia. Intern Med J. 2014;44:697\u20139.","journal-title":"Intern Med J"},{"key":"366_CR52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2010.45","volume":"24","author":"S Koehrer","year":"2010","unstructured":"Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia. 2010;24:1096\u20138.","journal-title":"Leukemia"},{"key":"366_CR53","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1182\/blood.V122.21.4186.4186","volume":"122","author":"N Jain","year":"2013","unstructured":"Jain N, Keating MJ, Burger JA, et al. A phase II trial of eltrombopag for patients with chronic lymphocytic leukemia (CLL) and thrombocytopenia. Blood. 2013;122:4186.","journal-title":"Blood"},{"key":"366_CR54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1179\/1607845412Y.0000000044","volume":"18","author":"L Xu","year":"2013","unstructured":"Xu L, Fang JP, Weng WJ, et al. Pure red cell aplasia associated with cytomegalovirus and Epstein-Barr virus infection in seven cases of Chinese children. Hematology. 2013;18:56\u20139.","journal-title":"Hematology"},{"key":"366_CR55","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/cid\/cis1046","volume":"56","author":"Y Crabol","year":"2013","unstructured":"Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968\u201377.","journal-title":"Clin Infect Dis"},{"key":"366_CR56","doi-asserted-by":"crossref","unstructured":"Dharmshaktu P, Gupta N, Dhanwal DK. Successful treatment of acquired pure red cell aplasia with oral corticosteroids in a patient with B-cell CLL. BMJ Case Rep. 2013.","DOI":"10.1136\/bcr-2013-201027"},{"key":"366_CR57","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","volume":"128","author":"RJ Means","year":"2016","unstructured":"Means RJ. Pure red cell aplasia. Blood. 2016;128:2504\u20139.","journal-title":"Blood"},{"key":"366_CR58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","volume":"142","author":"K Sawada","year":"2008","unstructured":"Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142:505\u201314.","journal-title":"Br J Haematol"},{"key":"366_CR59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2005.05.017","volume":"30","author":"K Narra","year":"2006","unstructured":"Narra K, Borghaei H, Al-Saleem T, et al. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res. 2006;30:109\u201314.","journal-title":"Leuk Res"},{"key":"366_CR60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2010.278","volume":"25","author":"J Rossignol","year":"2011","unstructured":"Rossignol J, Michallet AS, Oberic L, et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia. 2011;25:473\u20138.","journal-title":"Leukemia"},{"key":"366_CR61","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"366_CR62","doi-asserted-by":"crossref","unstructured":"Alzaki AA, Gerrie AS, Gillan TL, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: effect on outcome and survival, a population based analysis in British Columbia, Canada. Blood Conference: 56th Annual Meeting of the American Society of Hematology, ASH 2014;124.","DOI":"10.1182\/blood.V124.21.1945.1945"},{"key":"366_CR63","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2007-07-101303","volume":"111","author":"C Dearden","year":"2008","unstructured":"Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111:1820\u20136.","journal-title":"Blood"},{"key":"366_CR64","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3109\/10428194.2013.834054","volume":"55","author":"C Visco","year":"2013","unstructured":"Visco C, Cortelezzi A, Moretta F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? Leuk Lymphoma. 2013;55:1261\u20135.","journal-title":"Leuk Lymphoma"},{"key":"366_CR65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"J Byrd","year":"2013","unstructured":"Byrd J, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med"},{"key":"366_CR66","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"J Burger","year":"2015","unstructured":"Burger J, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"366_CR67","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"R Furman","year":"2014","unstructured":"Furman R, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370:2352\u20134.","journal-title":"N Engl J Med"},{"key":"366_CR68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","volume":"30","author":"K Rogers","year":"2016","unstructured":"Rogers K, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia autoimmune cytopenias during ibrutinib treatment. Leukemia. 2016;30:346\u201350.","journal-title":"Leukemia"},{"key":"366_CR69","first-page":"150","volume":"56","author":"M Montillo","year":"2016","unstructured":"Montillo M, O\u2019Brien S, Tedeschi A, et al. Ibrutinib in patients with autoimmune cytopenias and previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) from the phase 3 RESONATETM study. Leuk Lymphoma. 2016;56:150\u20131.","journal-title":"Leuk Lymphoma"},{"key":"366_CR70","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.3324\/haematol.2015.138289","volume":"102","author":"C Vitale","year":"2016","unstructured":"Vitale C, Ahn IE, Sivina M, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016;102:e254\u20138.","journal-title":"Haematologica"},{"key":"366_CR71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"B Lampson","year":"2016","unstructured":"Lampson B, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195\u2013203.","journal-title":"Blood"},{"key":"366_CR72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"R Furman","year":"2014","unstructured":"Furman R, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med"},{"key":"366_CR73","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0002-9343(55)90176-5","volume":"18","author":"L Wasserman","year":"1955","unstructured":"Wasserman L, Stats D, Schwartz L, Fudenberg H. Symptomatic and hemopathic hemolytic anemia. Am J Med. 1955;18:961\u201389.","journal-title":"Am J Med"},{"key":"366_CR74","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-016-2642-x","volume":"95","author":"G Carli","year":"2016","unstructured":"Carli G, Visco C, Falisi E, et al. Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. Ann Hematol. 2016;95:863\u201370.","journal-title":"Ann Hematol"},{"key":"366_CR75","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E","volume":"92","author":"J Cortes","year":"2001","unstructured":"Cortes J, O\u2019Brien S, Loscertales J, et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001;92:2016\u201322.","journal-title":"Cancer"},{"key":"366_CR76","doi-asserted-by":"crossref","unstructured":"Gomez-Almaguer D, Solano-Genesta, M, Cantu-Rodriguez, O, et al. Alemtuzumab and rituximab in the treatment of refractory autoimmune cytopenias. Blood Conference: 51st Annual Meeting of the American Society of Hematology, ASH New Orleans, LA United States 2009;114.","DOI":"10.1182\/blood.V114.22.4458.4458"},{"key":"366_CR77","first-page":"766","volume":"99","author":"C Gourguechon","year":"2014","unstructured":"Gourguechon C, Royer B, Marolleau JP. Evans syndrome management: a monocentric retrospective study of 11 cases. Haematologica. 2014;99:766\u20137.","journal-title":"Haematologica"},{"key":"366_CR78","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2009-04-215368","volume":"114","author":"M Michel","year":"2009","unstructured":"Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114:3167\u201372.","journal-title":"Blood"},{"key":"366_CR79","first-page":"320","volume":"99","author":"A Sharma","year":"2014","unstructured":"Sharma A, Geirnaert M, Banerji V, et al. A population based experience on the use of RCD or RCVP in autoimmune hemolytic anemia in CLL. Haematologica. 2014;99:320.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0366-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0366-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0366-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:19:23Z","timestamp":1692670763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0366-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0366-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}